Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitisGlobeNewsWire • 03/11/24
Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study showsReuters • 03/07/24
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticariaGlobeNewsWire • 02/24/24
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial ReportGlobeNewsWire • 02/23/24
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammationGlobeNewsWire • 02/23/24
Press Release: Sanofi's Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent DirectorsGlobeNewsWire • 02/22/24
Sanofi's consumer healthcare spin-off attracts private equity interest, sources sayReuters • 02/20/24
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)GlobeNewsWire • 02/16/24
This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less riskMarket Watch • 02/12/24
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial EfficiencyBusiness Wire • 02/06/24
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnessesGlobeNewsWire • 02/05/24
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.Investors Business Daily • 02/01/24